Literature DB >> 2512985

Synthesis of platelet-activating factor by human blood platelets and leucocytes. Evidence against selective utilization of cellular ether-linked phospholipids.

A Sturk1, M C Schaap, A Prins, J W ten Cate, H van den Bosch.   

Abstract

Synthesis of platelet activating factor (PAF) in blood platelet suspensions may be due to leucocyte contamination. We therefore investigated PAF synthesis in human blood platelet suspensions and granulocyte- (PMN)-enriched leucocyte suspensions upon stimulation by thrombin and Ca2+-ionophore A23187, both in the presence and absence of the presumed PAF catabolism inhibitor phenylmethylsulfonyl fluoride (PMSF). PAF synthesis was measured by aggregation of washed rabbit platelets and by [3H]acetate incorporation. In contrast to A23187, thrombin was unable to stimulate PAF synthesis by leucocytes. As thrombin did induce PAF synthesis by platelet suspensions, this was evidently not due to leucocyte contamination. A23187 also induced PAF synthesis by platelets, but this was dependent upon the platelet isolation method and possibly associated activation. The ratio of [3H]acetate incorporation into 1-alkyl- versus 1-acyl-2-acetylglycerophosphocholine upon stimulation of non-PMSF-treated leucocytes and platelets amounted to 12.8 and 1.2, respectively. These values are at least 10-fold higher than the ratio of 1-alkyl versus 1-acyl species in the cellular phosphatidylcholine precursor for PAF. By PMSF pretreatment, the distribution of incorporated [3H]acetate between 1-ether- and 1-ester-linked species became similar to that in the precursor phosphatidylcholines of the respective cell type, due to increased recovery of [3H]acetate in the acyl compounds. Both leucocyte and platelet homogenates rapidly degraded acylacetylglycerophosphocholine to (acetyl)glycerophosphocholine, and this deacylation was inhibited by PMSF pretreatment of the cells. We conclude that upon cell stimulation a phospholipase A2 converts both alkylacylglycerophosphocholine and diacylglycerophosphocholine to the 2-lysoanalogs in a ratio similar to the occurrence of the parent compounds. The acetyltransferase subsequently acetylates both compounds to acylacetylglycerophosphocholine and alkylacetylglycerophosphocholine (PAF), respectively. Deacylation of the 1-ester-linked species, either before or after acetylation, gives the impression of selective utilization of 1-ether-linked species for PAF production. It is only after inhibition of the deacylation by pretreatment of the cells with PMSF that a mainly nondiscriminative use of 1-ether- and 1-ester-linked species by both phospholipase A2 and acetyltransferase becomes evident.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2512985     DOI: 10.1016/0304-4165(89)90157-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  The role of platelet-activating factor and peptidoleukotrienes in the vascular changes of rat passive anaphylaxis.

Authors:  S Fernández-Gallardo; M A Gijón; C García; V Furio; F T Liu; M Sánchez Crespo
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF.

Authors:  Vyala Hanumanthareddy Chaithra; Shancy Petsel Jacob; Chikkamenahalli Lakshminarayana Lakshmikanth; Mosale Seetharam Sumanth; Kandahalli Venkataranganayaka Abhilasha; Chu-Huang Chen; Anita Thyagarajan; Ravi P Sahu; Jeffery Bryant Travers; Thomas M McIntyre; Kempaiah Kemparaju; Gopal Kedihithlu Marathe
Journal:  J Lipid Res       Date:  2018-08-23       Impact factor: 5.922

Review 3.  Structural and (patho)physiological diversity of PAF.

Authors:  R N Pinckard; D S Woodard; H J Showell; M J Conklyn; M J Novak; L M McManus
Journal:  Clin Rev Allergy       Date:  1994

Review 4.  Platelet-activating factor: the biosynthetic and catabolic enzymes.

Authors:  F Snyder
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

5.  Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase.

Authors:  C C Silliman; K L Clay; G W Thurman; C A Johnson; D R Ambruso
Journal:  J Lab Clin Med       Date:  1994-11

6.  Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation.

Authors:  E Ribaldi; A M Mezzasoma; E Francescangeli; M Prosdocimi; G G Nenci; G Goracci; P Gresele
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

7.  Factors that influence the proportions of platelet-activating factor and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine synthesized by the mast cell.

Authors:  M Triggiani; A N Fonteh; F H Chilton
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

8.  Studies on the selectivity of enzymes involved in platelet-activating factor formation in stimulated cells.

Authors:  H van den Bosch; A Sturk; J W ten Cate; A J Aarsman
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

9.  Novel mass spectral fragmentation of heptafluorobutyryl derivatives of acyl analogues of platelet-activating factor.

Authors:  S T Weintraub; R N Pinckard; T G Heath; D A Gage
Journal:  J Am Soc Mass Spectrom       Date:  1991-12       Impact factor: 3.109

10.  Platelets trigger perivascular mast cell degranulation to cause inflammatory responses and tissue injury.

Authors:  Jörn Karhausen; Hae Woong Choi; Krishna Rao Maddipati; Joseph P Mathew; Qing Ma; Yacine Boulaftali; Robert Hugh Lee; Wolfgang Bergmeier; Soman N Abraham
Journal:  Sci Adv       Date:  2020-03-18       Impact factor: 14.957

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.